Hikma Still Sees Value In Generic Advair Despite Teva’s US Approval
CEO Predicts Launch From Teva Later This Year; Also Comments On Vascepa Competition
Hikma expects healthy prospects for its US Advair generic in 2022, despite rival Teva recently receiving FDA approval for its own version. Meanwhile, Hikma CEO Siggi Olafsson also outlined expectations for generic competition on icosapent amid ongoing API shortages.
